HOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14th Annual East Coast IDEAS Conference at the Jay Conference Center – Bryant Park in New York City on June 12, 2024. About Harvard Bioscience, Inc. For more information, please visit our website at www.harvardbioscience.com. The Company's presentation is scheduled f ...

Company Overview - Harvard Bioscience, Inc. is a leading developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production, and preclinical testing for pharmaceutical and therapy development [5] - The company's customer base includes renowned academic institutions, government laboratories, and leading pharmaceutical, biotechnology, and contract research organizations [5] - Harvard Bioscience operates in North America, Europe, and China, utilizing both direct and distribution channels to reach customers globally [5] Investor Engagement - The company announced that Jim Green, Chairman and CEO, and Jennifer Cote, CFO, will present to investors at the 14th Annual East Coast IDEAS Conference on June 12, 2024 [4] - The presentation is scheduled for 2:45-3:20 PM ET and will be webcast live, with a replay available shortly after [2][4] - One-on-one investor meetings will also be hosted throughout the day, with scheduling available through the conference team [2]

HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, with a live fireside chat scheduled for 9:00-9:40 am ET. The Company will also be hosting one-on-one meetings with investors in conjunction with the Conference. To register for the presentation, or to schedul ...

HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, with a live fireside chat scheduled for 9:00-9:40 am ET. The Company will also be hosting one-on-one meetings with investors in conjunction with the Conference. To register for the presentation, or to schedule ...

For the transition period from to Commission file number 001-33957 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (State or other jurisdiction of Incorporation or organization) (I.R.S. Employer Identification No.) 84 October Hill Road, Holliston, Massa ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants Dave Sirois - Director, SEC Reporting Jim Green - Chairman, President and CEO Jennifer Cote - CFO Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Frank DiLorenzo - Singular Research Operator Good day, and thank you for standing by. Welcome to the Q1 2024 Harvard Bioscience Inc. Earnings Conference Call. [Operator Instructions] Please be advised that tod ...

Harvard Bioscience (HBIO) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this medical instruments maker would post earnings of $0.05 per share when it actually produced earnings of $0.04, delivering a surprise of -20%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Harvard ...

Exhibit 99.1 | Financial Results Summary | | | Three Months Ended March 31, | | | --- | --- | --- | --- | --- | | (unaudited, $ in millions except per share data) | | 2024 | | 2023 | | Revenues | $ | 24.5 | $ | 30.0 | | Gross margin | | 60.3% | | 61.2% | | Operating (loss) income (GAAP) | $ | (2.3) | $ | 1.7 | | Adjusted operating income | $ | 1.2 | $ | 4.4 | | Net (loss) income (GAAP) | $ | (4.7) | $ | 0.6 | | Diluted (loss) earnings per share (GAAP) | $ | (0.11) | $ | 0.01 | | Diluted adjusted earnings pe ...

HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2024 before the market opens on May 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast ...

HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2024 before the market opens on May 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast sh ...